Plasmacytoid dendritic cells in autoimmunity

Current Opinion in Immunology

Volumn 44, Issue , 2017, Pages 20-25

  Panda, Santosh K ^a   Kolbeck, Roland ^a   Sanjuan, Miguel A ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANIFROLUMAB; AUTOANTIBODY; BELIMUMAB; BIIB 059; CPG 52365; DV 1179; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; MEDI 7734; NUCLEIC ACID; PF 06650833; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; DNA; IMMUNOGLOBULIN G; INTERFERON;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOPHAGY; CELL FUNCTION; CYTOKINE RELEASE; DERMATOMYOSITIS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; POLYMYOSITIS; REVIEW; SJOEGREN SYNDROME; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VIRUS INFECTION; ANIMAL; ANTIGEN ANTIBODY COMPLEX; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNITY; DENDRITIC CELLS; DNA; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; SELF TOLERANCE;

EID: 84994745646     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.10.006     Document Type: Review

References (54)

1. 1 Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D.W., Schmitz, J., BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165 (2000), 6037–6046.
2. 2 Rissoan, M.C., Duhen, T., Bridon, J.M., Bendriss-Vermare, N., Peronne, C., de Saint Vis, B., Briere, F., Bates, E.E., Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 100 (2002), 3295–3303.
3. 3 Gilliet, M., Cao, W., Liu, Y.J., Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8 (2008), 594–606.
4. 4 Beutler, B., Eidenschenk, C., Crozat, K., Imler, J.L., Takeuchi, O., Hoffmann, J.A., Akira, S., Genetic analysis of resistance to viral infection. Nat Rev Immunol 7 (2007), 753–766.
5. 5 Jego, G., Palucka, A.K., Blanck, J.P., Chalouni, C., Pascual, V., Banchereau, J., Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 (2003), 225–234.
6. 6 Swiecki, M., Colonna, M., The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 15 (2015), 471–485.
7. 7 Baechler, E.C., Batliwalla, F.M., Reed, A.M., Peterson, E.J., Gaffney, P.M., Moser, K.L., Gregersen, P.K., Behrens, T.W., Gene expression profiling in human autoimmunity. Immunol Rev 210 (2006), 120–137.
8. 8 Higgs, B.W., Liu, Z., White, B., Zhu, W., White, W.I., Morehouse, C., Brohawn, P., Kiener, P.A., Richman, L., Fiorentino, D., et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70 (2011), 2029–2036.
9. 9 Crow, M.K., Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am 36 (2010), 173–186 x.
10. 10 Di Domizio, J., Cao, W., Fueling autoimmunity: type I interferon in autoimmune diseases. Expert Rev Clin Immunol 9 (2013), 201–210.
11. ••].
12. 12•• Furie, R.M.J., Werth, V.P., Khamashta, M., Kalunian, K., Brohawn, P., Illei, G., Drappa, J., Wang, L., Yoo, S., Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe systematic lupus erythematosus (SLE). Arthritis Rheumatol, 67(Suppl 10), 2015 These two articles contain the results of two phase 2 clinical trial for molecules blocking Type I IFN receptor or blocking IFN-α. The primary endpoint was met in both studies, validating the role of Type I IFNs in SLE.
13. 13 Swiecki, M., Gilfillan, S., Vermi, W., Wang, Y., Colonna, M., Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity 33 (2010), 955–966.
14. 14 Cervantes-Barragan, L., Lewis, K.L., Firner, S., Thiel, V., Hugues, S., Reith, W., Ludewig, B., Reizis, B., Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc Natl Acad Sci U S A 109 (2012), 3012–3017.
15. 15• McNab, F., Mayer-Barber, K., Sher, A., Wack, A., O'Garra, A., Type I interferons in infectious disease. Nat Rev Immunol 15 (2015), 87–103 Here the authors review the importance of type-1 interferons in infectious diseases and recent controversies.
16. 16 Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 (2005), 19–28.
17. 17 O'Brien, M., Manches, O., Bhardwaj, N., Plasmacytoid dendritic cells in HIV infection. Adv Exp Med Biol 762 (2013), 71–107.
18. 18 Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., Borrow, P., Tough, D.F., Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4 (2003), 1009–1015.
19. 19 Cao, Y., Zhang, R., Zhang, W., Zhu, C., Yu, Y., Song, Y., Wang, Q., Bai, L., Liu, Y., Wu, K., et al. IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol 192 (2014), 691–703.
20. 20 Wu, V., Smith, A.A., You, H., Nguyen, T.A., Ferguson, R., Taylor, M., Park, J.E., Llontop, P., Youngman, K.R., Abramson, T., Plasmacytoid dendritic cell-derived IFNalpha modulates Th17 differentiation during early Bordetella pertussis infection in mice. Mucosal Immunol 9 (2016), 777–786.
21. 21 Abou Rahal, J., Kurban, M., Kibbi, A.G., Abbas, O., Plasmacytoid dendritic cells in alopecia areata: missing link?. J Eur Acad Dermatol Venereol 30 (2016), 119–123.
22. 22 Saadeh, D., Kurban, M., Abbas, O., Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol 25 (2016), 415–421.
23. 23 Crow, M.K., Kirou, K.A., Wohlgemuth, J., Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36 (2003), 481–490.
24. 24 Baechler, E.C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., Ortmann, W.A., Espe, K.J., Shark, K.B., Grande, W.J., Hughes, K.M., Kapur, V., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100 (2003), 2610–2615.
25. 25 Bennett, L., Palucka, A.K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J., Pascual, V., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197 (2003), 711–723.
26. 26 Wenzel, J., Tuting, T., An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis. J Invest Dermatol 128 (2008), 2392–2402.
27. 27 Tucci, M., Quatraro, C., Lombardi, L., Pellegrino, C., Dammacco, F., Silvestris, F., Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 58 (2008), 251–262.
28. 28•• Sisirak, V., Ganguly, D., Lewis, K.L., Couillault, C., Tanaka, L., Bolland, S., D'Agati, V., Elkon, K.B., Reizis, B., Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J Exp Med 211 (2014), 1969–1976 Here the authors demonstrated the central role of pDCs in disease using lupus prone mouse models by targeting the transcription factor E2-2 that results in non-functional pDCs.
29. 29•• Rowland, S.L., Riggs, J.M., Gilfillan, S., Bugatti, M., Vermi, W., Kolbeck, R., Unanue, E.R., Sanjuan, M.A., Colonna, M., Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 211 (2014), 1977–1991 Using a transient depletion of pDCs in a lupus prone model, this article shows pDC are key initiator of the inflammatory cascade that underlies the disease in mouse.
30. 30 Kobayashi, T., Shimabukuro-Demoto, S., Yoshida-Sugitani, R., Furuyama-Tanaka, K., Karyu, H., Sugiura, Y., Shimizu, Y., Hosaka, T., Goto, M., Kato, N., et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity 41 (2014), 375–388.
31. 31 Mouchess, M.L., Arpaia, N., Souza, G., Barbalat, R., Ewald, S.E., Lau, L., Barton, G.M., Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation. Immunity 35 (2011), 721–732.
32. 32 Marshak-Rothstein, A., Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6 (2006), 823–835.
33. 33 Lovgren, T., Eloranta, M.L., Bave, U., Alm, G.V., Ronnblom, L., Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 50 (2004), 1861–1872.
34. 34 Henault, J., Martinez, J., Riggs, J.M., Tian, J., Mehta, P., Clarke, L., Sasai, M., Latz, E., Brinkmann, M.M., Iwasaki, A., et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 37 (2012), 986–997.
35. 35 Sasai, M., Linehan, M.M., Iwasaki, A., Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329 (2010), 1530–1534.
36. 36 Harley, J.B., Alarcon-Riquelme, M.E., Criswell, L.A., Jacob, C.O., Kimberly, R.P., Moser, K.L., Tsao, B.P., Vyse, T.J., Langefeld, C.D., Nath, S.K., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40 (2008), 204–210.
37. 37 Han, J.W., Zheng, H.F., Cui, Y., Sun, L.D., Ye, D.Q., Hu, Z., Xu, J.H., Cai, Z.M., Huang, W., Zhao, G.P., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41 (2009), 1234–1237.
38. 38 Weindel, C.G., Richey, L.J., Bolland, S., Mehta, A.J., Kearney, J.F., Huber, B.T., B cell autophagy mediates TLR7-dependent autoimmunity and inflammation. Autophagy 11 (2015), 1010–1024.
39. 39• Martinez, J., Cunha, L.D., Park, S., Yang, M., Lu, Q., Orchard, R., Li, Q.Z., Yan, M., Janke, L., Guy, C., et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature 533 (2016), 115–119 This article demonstrated the role of LC3-associated phagocytosis (LAP) in clearance of dying cells and its contribution to initiation of auto-inflammatory pathway during SLE.
40. 40 Ravichandran, K.S., Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 207 (2010), 1807–1817.
41. 41 Tian, J., Avalos, A.M., Mao, S.Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8 (2007), 487–496.
42. 42 Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.H., Homey, B., Cao, W., Su, B., Nestle, F.O., Zal, T., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007), 564–569.
43. 43 Sandgren, S., Wittrup, A., Cheng, F., Jonsson, M., Eklund, E., Busch, S., Belting, M., The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 279 (2004), 17951–17956.
44. 44 Garcia-Romo, G.S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z., Punaro, M., Baisch, J., Guiducci, C., Coffman, R.L., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med, 3, 2011 73ra20.
45. 45•• Henault, J., Riggs, J.M., Karnell, J.L., Liarski, V.M., Li, J., Shirinian, L., Xu, L., Casey, K.A., Smith, M.A., Khatry, D.B., et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat Immunol 17 (2016), 196–203 Here the authors demonstrated that self-reactive IgE are found in SLE patients and that they trigger pDC responses including the secretion of pathogenic Type I IFNs. Self-reactive IgE work in synergy with IgG autoantibodies.
46. 46 Sanjuan, M.A., Sagar, D., Kolbeck, R., Role of IgE in autoimmunity. J Allergy Clin Immunol 137 (2016), 1651–1661.
47. 47 Schroeder, J.T., Chichester, K.L., Bieneman, A.P., Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha. J Allergy Clin Immunol 121 (2008), 486–491.
48. 48 Gill, M.A., Bajwa, G., George, T.A., Dong, C.C., Dougherty, I.I., Jiang, N., Gan, V.N., Gruchalla, R.S., Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 184 (2010), 5999–6006.
49. 49 Swiecki, M., Colonna, M., Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 234 (2010), 142–162.
50. 50 Yildirim-Toruner, C., Diamond, B., Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127 (2011), 303–312 quiz 313-304.
51. 51 Lutalo, P.M., D'Cruz, D.P., Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther 14 (2014), 1701–1708.
52. 52 Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, J., Maciuca, R., Zhang, D., Garg, J.P., Brunetta, P., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
53. 53 Kalunian, K.C., Merrill, J.T., Maciuca, R., McBride, J.M., Townsend, M.J., Wei, X., Davis, J.C. Jr., Kennedy, W.P., A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 75 (2016), 196–202.
54. 54 Pellerin, A., Otero, K., Czerkowicz, J.M., Kerns, H.M., Shapiro, R.I., Ranger, A.M., Otipoby, K.L., Taylor, F.R., Cameron, T.O., Viney, J.L., et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med 7 (2015), 464–476.